132 search results for: type 2 inflammation

expert video

Emerging Understanding of Chronic Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU

68 min

Dermatology

Review the roles of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

ESPGHAN <b>2</b>0<b>2</b>4 | Shedding Light on Pediatric Eosinophilic Esophagitis: Timely Identification and Management

expert video

ESPGHAN 2024 | Shedding Light on Pediatric Eosinophilic Esophagitis: Timely Identification and Management

35 min

Gastroenterology

Prof. Salvatore Oliva and Dr. Dhandapani Ashok discuss the burden of type 2 inflammation in pediatric EoE and the importance of early diagnosis and management.

expert video

Skin Barrier Dysfunction in AD

4 min

Dermatology

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.

expert video

Dysbiosis, Skin Infections, and Itch

3 min

Dermatology

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel presents how type 2 inflammation contributes to dysbiosis, skin infections, and itch in patients with AD.

UCARE <b>2</b>0<b>2</b>3: Neuronal Involvement in CSU

expert video

UCARE 2023: Neuronal Involvement in CSU

7 min

Dermatology

Dr. Kim provides a deep dive into the neuroimmune axis in CSU.

UCARE <b>2</b>0<b>2</b>3: Immune Cells and Mediators Essential for Driving CSU Pathology

expert video

UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

1 min

Dermatology

Dr. Saini describes immune cells and mediators beyond mast cells that are also essential for helping to drive CSU pathology.

Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

5 min

Dermatology

An infographic summarizing the clinical manifestations and pathophysiological processes of PN.

expert video

ESPGHAN 2024 | Burden and Timely Recognition of Pediatric EoE

13 min

Gastroenterology

Dr. Dhandapani Ashok discusses patient and caregiver burden in pediatric EoE and the challenges with identifying EoE in a young patient population.

expert video

Managing the Risk of Fibrostenosis in EoE

2 min

Gastroenterology

Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.

UCARE <b>2</b>0<b>2</b>3: Non-Histaminergic Neuronal Sensitization in CSU

expert video

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

1 min

Dermatology

Dr. Kim highlights the role of non-histaminergic neuronal sensitization in CSU via cytokines.

expert video

EAACI 2022 | Hard to Swallow: Identifying and Managing EoE in the Allergy Clinic

21 min

Gastroenterology

Experts Prof. Ingrid Terreehorst and Prof. Arjan Bredenoord discuss the allergist’s perspective on identifying and management of patients with EoE.

ERS <b>2</b>0<b>2</b>4 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

expert video

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

45 min

Pulmonology

Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BelgiumChange country/region